A Study of Donanemab (LY3002813) in Healthy Chinese Participants
Clinical trial NCT05533411 · COMPLETED
Trial details
- NCT number
- NCT05533411
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-14
- Primary completion
- 2023-01-05
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.